Get the Stockscreener App
7.38
0.00%
0.00
After Hours:
7.30
-0.08
-1.08%
Immunitybio Inc stock is traded at $7.38, with a volume of 14.36M.
It is up +0.00% in the last 24 hours and down -24.54% over the past month.
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.
See More
Previous Close:
$7.38
Open:
$7.37
24h Volume:
14.36M
Relative Volume:
0.40
Market Cap:
$7.59B
Revenue:
$113.29M
Net Income/Loss:
$-351.47M
P/E Ratio:
-18.93
EPS:
-0.3898
Net Cash Flow:
$-309.19M
1W Performance:
-12.87%
1M Performance:
-24.54%
6M Performance:
+190.55%
1Y Performance:
+119.64%
1-Day Range:
$7.13
$7.65
1-Week Range:
$6.54
$9.54
52-Week Range:
$1.83
$12.43
Immunitybio Inc Stock (IBRX) Company Profile
Name
Immunitybio Inc
Sector
Industry
Phone
(844) 696-5235
Address
3530 JOHN HOPKINS COURT, SAN DIEGO
Compare IBRX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IBRX
Immunitybio Inc
|
7.38 | 7.59B | 113.29M | -351.47M | -309.19M | -0.3898 |
VRTX
Vertex Pharmaceuticals Inc
|
433.07 | 110.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
737.71 | 77.99B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
691.40 | 42.91B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
317.36 | 42.09B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
283.03 | 31.42B | 5.36B | 287.73M | 924.18M | 2.5229 |
Immunitybio Inc Stock (IBRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-12-26 | Resumed | BTIG Research | Buy |
| May-20-25 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-06-25 | Initiated | H.C. Wainwright | Buy |
| Jan-10-25 | Initiated | BTIG Research | Buy |
| May-12-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-03-22 | Initiated | Jefferies | Buy |
View All
Immunitybio Inc Stock (IBRX) Latest News
IBRX INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that ImmunityBio, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - mydailyrecord.com
Biotech Company Achieves Key Bladder Cancer Milestone in California - Streetwise Reports
ImmunityBio plunges after getting FDA warning on cancer drug - msn.com
Portnoy Law Firm Announces Class Action on Behalf of ImmunityBio, Inc. Investors - National Today
IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit First Filed By the Firm - The Malaysian Reserve
ImmunityBio, Inc. (IBRX) Faces Securities Class Action Amid - GlobeNewswire
ImmunityBio, Inc. (IBRX) Faces Securities Class Action Amid FDA Warning Regarding Unsupported Cancer Treatment Claims, $2 Billion Market Capitalization Wiped Out – Hagens Berman - GlobeNewswire Inc.
IBRX ALERT: Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of ImmunityBio, Inc. Investors - Business Wire
IBRX DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds ImmunityBio (IB - The National Law Review
ImmunityBio Inc Trade Ideas — LS:A2QQ2E - TradingView
IBRX DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026 - Bluefield Daily Telegraph
Shareholders Urged to Join Class Action Lawsuit Against ImmunityBio - National Today
ImmunityBio, Soon-Shiong Sued by Investor Over FDA Admonition - news.bloomberglaw.com
IBRX INVESTOR ALERT: ImmunityBio, Inc. Investors with Substantial Losses Have Opportunity to Lead the ImmunityBio Class Action Lawsuit - PR Newswire
IBRX Stockholder Alert: Shareholder Rights Law Firm Robbins - GlobeNewswire
$IBRX Lawsuit: ImmunityBio, Inc. Sued for Securities Fraud; - GlobeNewswire
ImmunityBio (IBRX) price target increased by 15.63% to 15.10 - msn.com
ImmunityBio vs. Moderna: Which Biotech Has More Upside Potential? - Yahoo Finance
ImmunityBio Confirms Trial Strength For Anktiva In Bladder Cancer - stocktwits.com
ImmunityBio Confirms Statistical Power in Pivotal Randomized BCG-Naïve NMIBC Trial to Detect Clinically Meaningful Differences Between ANKTIVA® Plus BCG Versus BCG Alone; Supplemental BLA Submission on Track for 2026 - BioSpace
Rosen Law Firm Files Securities Class Action Lawsuit Against ImmunityBio - National Today
Robbins LLP Informs Investors of ImmunityBio Class Action Lawsuit - National Today
Investor Notice: Robbins LLP Informs Investors of the ImmunityBio, Inc. Class Action Lawsuit - PharmiWeb.com
ROSEN, THE FIRST FILING FIRM, Encourages ImmunityBio, Inc. - GlobeNewswire
ROSEN, THE FIRST FILING FIRM, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before ... - Caledonian Record
IBRX INVESTOR ALERT: ImmunityBio, Inc. Investors with - GlobeNewswire
EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit on Behalf of ImmunityBio, Inc. Investors – IBRX - The AI Journal
Kaplan Fox Announces an Investigation Into ImmunityBio, Inc. (IBRX) for Possible Securities Law Violations - NewMediaWire
IBRX Stock Still A Buy After Worst Day In Over A Year? Why This Analyst Is Shrugging Off FDA Warning Letter - Stocktwits
ImmunityBio (IBRX) soars 11% as Asian expansion looms - MSN
ImmunityBio Lead Bladder Cancer Drug Trial Clears Power Check - benzinga.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ImmunityBio, Inc.IBRX - PR Newswire
ImmunityBio bladder cancer trial deemed adequately powered by IDMC - Investing.com Canada
ImmunityBio, Inc. announced that its pivotal randomized BCG-naive non-muscle invasive bladder cancer (NMIBC) trial has demonstrated sufficient statistical power to detect clinically meaningful differences between the Anktiva® plus BCG treatment regimen a - Bitget
FDA Warning Puts ImmunityBio Anktiva Hopes And Valuation In Focus - Yahoo Finance
IBRX SEC FilingsImmunitybio Inc 10-K, 10-Q, 8-K Forms - Stock Titan
FDA Warns ImmunityBio Over Misleading Cancer Drug Claims - National Today
Why ImmunityBio Stock Is Up More Than 11% Today - AOL.com
Soon-Shiong’s Drug Deception - status.news
IBRX Stock Is Back: Anktiva Now Targets Severe Pneumonia After Clearing Key Checkpoint In Bladder Cancer Trial - Stocktwits
FDA Warning On Anktiva Puts ImmunityBio Growth Story Under Scrutiny - simplywall.st
ImmunityBio (NASDAQ:IBRX) Trading Up 8.9%Still a Buy? - MarketBeat
Why is ImmunityBio (IBRX) down 35.8% since last earnings report? - msn.com
FDA Objects to Claims by Soon-Shiong on Cancer Drug - newser.com
FDA Issues Warning Letter to ImmunityBio | PharmExec - Pharmaceutical Executive
Why the FDA flagged ImmunityBio’s ‘false and misleading’ claims in podcast, TV spot - Medical Marketing and Media
ImmunityBio’s Global Expansion Raises Stock Speculation - timothysykes.com
Unapproved Anktiva claims earn Immunitybio FDA warning - BioWorld MedTech
Why Is ImmunityBio (IBRX) Down 35.8% Since Last Earnings Report? - Yahoo Finance
ImmunityBio Inc. (IBRX) Announces Approval for ANKTIVA® in Macau SAR, China - Yahoo Finance
FDA Sends Warning Letter to ImmunityBio for Misleading Claims in Advertisement - Pharmaceutical Executive
Immunitybio Inc Stock (IBRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Immunitybio Inc Stock (IBRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Selecky Christobel | Director |
Feb 23 '26 |
Option Exercise |
2.98 |
25,000 |
74,500 |
25,000 |
| Selecky Christobel | Director |
Feb 23 '26 |
Sale |
10.00 |
25,000 |
250,000 |
0 |
| Sachs David C. | Chief Financial Officer |
Feb 22 '26 |
Option Exercise |
0.00 |
40,650 |
0 |
320,825 |
| SOON-SHIONG PATRICK | See remarks |
Feb 22 '26 |
Option Exercise |
0.00 |
114,329 |
0 |
29,816,081 |
| LAUER REGAN J | Chief Accounting Officer |
Feb 22 '26 |
Option Exercise |
0.00 |
4,065 |
0 |
117,548 |
| Adcock Richard | CEO & President |
Feb 22 '26 |
Option Exercise |
0.00 |
152,439 |
0 |
637,904 |
| Simon Barry J. | Director |
Feb 22 '26 |
Option Exercise |
0.00 |
15,243 |
0 |
3,096,847 |
| Simon Barry J. | Director |
Feb 23 '26 |
Sale |
10.25 |
165,000 |
1,691,102 |
2,925,821 |
| Simon Barry J. | Director |
Feb 20 '26 |
Sale |
9.25 |
10,000 |
92,500 |
3,081,604 |
3.03%
2.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):